AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo.

about

AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo.

Item

http://www.wikidata.org/entity/Q49711997

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

AZA-MS: a novel multiparameter ...... f azacitidine therapy in vivo.

@en

AZA-MS: a novel multiparameter ...... f azacitidine therapy in vivo.

@nl

type

Item

label

AZA-MS: a novel multiparameter ...... f azacitidine therapy in vivo.

@en

AZA-MS: a novel multiparameter ...... f azacitidine therapy in vivo.

@nl

prefLabel

AZA-MS: a novel multiparameter ...... f azacitidine therapy in vivo.

@en

AZA-MS: a novel multiparameter ...... f azacitidine therapy in vivo.

@nl

P1476

AZA-MS: a novel multiparameter ...... f azacitidine therapy in vivo.

@en

P2093

A C Nunez

http://www.w3.org/2001/XMLSchema#string

A N Q Vo

http://www.w3.org/2001/XMLSchema#string

J E Pimanda

http://www.w3.org/2001/XMLSchema#string

L B Hesson

http://www.w3.org/2001/XMLSchema#string

M J Raftery

http://www.w3.org/2001/XMLSchema#string

R Pickford

http://www.w3.org/2001/XMLSchema#string

P2860

Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

The World Health Organization (WHO) classification of the myeloid neoplasms

5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines

Reassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposure

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Identification of direct targets and modified bases of RNA cytosine methyltransferases.

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

P2888

leu.2017.340

P304

900-910

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2017.340

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ashwin Unnikrishnan

Arjun Verma

P577

2017-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1099697983

http://www.w3.org/2001/XMLSchema#string

P698

29249821

http://www.w3.org/2001/XMLSchema#string

P932

5886051

http://www.w3.org/2001/XMLSchema#string